ANMCO POSITION PAPER: cardio-oncology in the COVID era (CO and CO)
Irma Bisceglia(Azienda Ospedaliera San Camillo-Forlanini), Furio Colivicchi(Ospedale San Filippo Neri), Luigi Tarantini(Santa Maria Nuova Hospital), Giuseppina Gallucci, Stefania Angela Di Fusco(ASL Roma), Paolo Trambaiolo(Ospedale Sandro Pertini), Fabiana Lucà(Azienda ospedaliera "Bianchi-Melacrino-Morelli"), Michele Massimo Gulizia(Ospedale Garibaldi), Giulia Russo(University of Catania), Domenico Gabrielli(Azienda Ospedaliera San Camillo-Forlanini), Vincenzo Quagliariello(Cancer Institute (WIA)), Stefano Oliva(Istituto Tumori Bari), Nicola Maurea(Cancer Institute (WIA)), Fabio Maria Turazza, Iris Parrini(A. O. Ordine Mauriziano di Torino), Maria Laura Canale(Ospedale Versilia), Chiara Lestuzzi
Cited by 8
Related Papers
The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin
|Cardiovascular Diabetology|2021|368
In silico clinical trials: concepts and early adoptions
|Briefings in Bioinformatics|2018|267
Prevalence and Prognostic Impact of Non-Cardiac Co-Morbidities in Heart Failure Outpatients with Preserved and Reduced Ejection Fraction: A Community-Based Study
|European Journal of Heart Failure|2018|174
Trastuzumab Adjuvant Chemotherapy and Cardiotoxicity in Real-World Women With Breast Cancer
|Journal of Cardiac Failure|2011|116
Metabolic syndrome affects breast cancer risk in postmenopausal women: National Cancer Institute of Naples experience
|Cancer Biology & Therapy|2010|108